0001564590-22-012215.txt : 20220329 0001564590-22-012215.hdr.sgml : 20220329 20220329162350 ACCESSION NUMBER: 0001564590-22-012215 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220328 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220329 DATE AS OF CHANGE: 20220329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fulgent Genetics, Inc. CENTRAL INDEX KEY: 0001674930 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 812621304 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37894 FILM NUMBER: 22781172 BUSINESS ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 BUSINESS PHONE: 626-350-0537 MAIL ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 FORMER COMPANY: FORMER CONFORMED NAME: Fulgent Diagnostics, Inc. DATE OF NAME CHANGE: 20160517 8-K 1 flgt-8k_20220328.htm 8-K flgt-8k_20220328.htm
false 0001674930 0001674930 2022-03-28 2022-03-28

!

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 28, 2022

 

FULGENT GENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-37894

81-2621304

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

4978 Santa Anita Avenue

Temple City, California

 

91780

(Address of Principal Executive Offices)

 

(Zip Code)

 

(626) 350-0537

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

FLGT

 

The Nasdaq Stock Market 
(Nasdaq Global Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 28, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”), in accordance with the recommendation of the Compensation Committee of the Board, adopted the Incentive Compensation Recoupment Policy (the “Clawback Policy”). The Clawback Policy, which is administered by the Compensation Committee of the Board (the “Committee”), permits the Committee to seek recoupment of incentive compensation granted or awarded to or earned by the Company’s employees who are “officers” under the reporting requirements of Section 16 of the Exchange Act (individually, an “Executive”), in the event the Committee determines that an Executive engaged in serious misconduct, or failed to supervise a subordinate employee who engaged in serious misconduct which the Executive knew, or was reckless in not knowing, was occurring, and such misconduct resulted in a material violation of law or a written Company policy that caused significant financial or reputational harm to the Company. For purposes of the Clawback Policy, incentive compensation means (i) any equity or equity-based award granted on or after the Effective Date, and (ii) any cash-based performance or incentive award (i.e., bonus or cash incentive plan payment, including any amounts deferred with respect thereto) approved, awarded or granted to an Executive on or after the Effective Date. The Clawback Policy provides that the Committee may not seek recoupment of incentive compensation following a change in control or that was awarded more than three years prior to the first event giving rise to the recoupment. Notwithstanding the Policy, the Company may recoup compensation to the extent required by law or the requirements of the exchange on which the Company’s stock is listed for trading.

The foregoing description of the terms of the Clawback Policy does not purport to be complete and is qualified in its entirety by reference to the full text of the Clawback Policy, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

 

Exhibit

No.

 

Description

 

 

 

10.1*

 

Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Management contract or compensatory plan, contract or arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 29, 2022

FULGENT GENETICS, INC.

 

 

 

 

 

By:

 

/s/ Paul Kim

 

Name:

 

Paul Kim

 

Title:

 

Chief Financial Officer

 

 EX-10.1 2 flgt-ex101_7.htm EX-10.1 flgt-ex101_7.htm

Exhibit 10.1

 

FULGENT GENETICS, INC.

INCENTIVE COMPENSATION RECOUPMENT POLICY

Fulgent Genetics, Inc. has adopted this Incentive Compensation Recoupment Policy, which is effective as of March 28, 2022 (the “Effective Date”).

1.Certain Definitions.

(a)“Board” means the Board of Directors of the Company.

(b)“Committee” means the Compensation Committee of the Board.

(c)“Company” means Fulgent Genetics, Inc., a corporation incorporated under the laws of the State of Delaware.

(d)“Effective Date” shall have the meaning as set forth above.

(e)“Executive” means an employee of the Company or any subsidiary of the Company, who is serving as an “officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended.

(f)“Incentive Compensation” means (i) any equity or equity-based award granted on or after the Effective Date, and (ii) any cash-based performance or incentive award (i.e., bonus or cash incentive plan payment, including any amounts deferred with respect thereto) approved, awarded or granted to an Executive on or after the Effective Date.

(g)“Policy” means this Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy.

(h)“Recoupment” (and “Recoup”) includes (a) the recovery, in whole or in part, of Incentive Compensation already paid, (b) forfeiture, recapture, reduction or cancellation, in whole or in part, of Incentive Compensation awarded or granted over which the Company retains control, and (c) the reduction, in whole or in part, of current or future Incentive Compensation.

(i)“Recoverable Payment” is the term that is used to describe amounts subject to Recoupment under this Policy, and means any Incentive Compensation after the Effective Date, to the extent granted or awarded to or earned by the Executive in respect of services as an employee, all as determined by the Committee.

2.Administration of this Policy.

This Policy will be administered by the Committee, which will consider the facts and circumstances related to possible Recoupment decisions and make determinations in its discretion regarding seeking Recoupment. Any determination to seek Recoupment under this Policy shall only be made after providing the Executive, upon his or her request, a reasonable opportunity to appear before the Committee to present his or her position regarding the alleged misconduct being considered by the Committee and to present and explain any exculpatory and/or mitigating information and related documents that he or she believes to be relevant.

In administering this Policy, the Committee shall have the following powers, which it may exercise in its discretion, subject to and not inconsistent with the express provisions of this Policy: (i) to exercise all the power and authority either specifically granted to it under this Policy or reasonably necessary or advisable in the administration of this Policy; (ii) to determine whether, to what extent and under what circumstances to pursue Recoupment; (iii) to determine the Executive or Executives from whom to seek Recoupment; (iv) to interpret this Policy; (v) to prescribe, amend and rescind rules and regulations relating to this Policy; and (vi) to make all other determinations deemed reasonably necessary or advisable for the administration of this Policy.

The decisions of the Committee as to all questions of interpretation, application and administration of this Policy shall be presumed to be made in good faith and in the exercise of reasonable business judgment, but nothing contained herein shall prevent an Executive from challenging on legal grounds a Recoupment determination.

 

 

3.Recoupment.

On and after the Effective Date of this Policy, the Committee may seek Recoupment of any Recoverable Payment, when in its judgment, after reviewing relevant facts and circumstances, it determines that: (a) an Executive (i) engaged in serious misconduct, or (ii) failed to supervise a subordinate employee who engaged in serious misconduct which the Executive knew, or was reckless in not knowing, was occurring, and (b) such misconduct resulted in a material violation of law or a written Company policy that caused significant financial or reputational harm to the Company. As used in this Policy, “serious misconduct” may be found to have occurred only where an Executive or a supervised employee acted knowingly, intentionally, or recklessly in violating a law or written Company policy. For the avoidance of doubt, an Executive’s business judgment made in good faith and in the reasonable belief that such judgments and related actions were in or not opposed to the best interests of the Company shall not subject the Executive’s Incentive Compensation to Recoupment.

The determination by the Committee whether and the extent to which to seek Recoupment may be influenced by a variety of factors, including, but not limited to, (i) the elements of the compensation received by the Executive, (ii) retention, promotion, or succession planning considerations, (iii) pay equity factors, (iv) whether the underlying conduct was an isolated occurrence, (v) feasibility and cost of implementation, (vi) legal and compliance factors, (vii) whether other disciplinary actions have been taken against the Executive, and (viii) the objective of administering the Policy in a way that does not discourage settlement of disputes when settlements are in the best long-term interests of the Company and its stockholders.

Based on the facts and circumstances, the Committee may decide on the appropriate Recoupment method, including whether to seek Recoupment of Recoverable Payments already paid or otherwise seek Recoupment (totally or partially) of Recoverable Payments that have not vested or have not been paid. However, the Committee may not seek Recoupment of any Recoverable Payments (a) following a change in control (as defined in the Executive’s severance agreement) or (b) that were awarded more than three years prior to the first event giving rise to the Recoupment. Recoupment determinations pursuant to this Policy shall only be made to the extent permitted by law, and this Policy shall be interpreted so as not to violate any law or regulation.

4.Indemnification.

The Company shall not indemnify any Executive against (i) the loss of any incorrectly awarded Incentive Compensation or any Incentive Compensation that is recouped pursuant to the terms of this Policy, or (ii) any claims relating to the Company’s enforcement of its rights under this Policy.

5.Miscellaneous.

This Policy shall not be construed to require Recoupment or create a presumption that Recoupment shall be sought in any particular case. Notwithstanding this Policy, the Company may, to the extent required by law (including, without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act) or the requirements of an exchange on which the Company’s shares are listed for trading, in each case as in effect from time to time, recoup compensation of whatever kind at any time from any applicable employee or former employee of the Company.

Public disclosure concerning Recoupment decisions shall be made in compliance with the rules and regulations of the Securities and Exchange Commission and other applicable laws, including without limitation, Item 402(b) of Regulation S-K, reasonably interpreted and applied. Where the Company deems it appropriate, it may provide disclosure beyond that required by law.

The Recoupment remedies provided herein are not intended to be exclusive. In the event of any misconduct or supervisory failure described in Section 3 above, the Company may take any actions that it deems appropriate to remedy the misconduct or supervisory failure and/or prevent its recurrence, including, but not limited to, dismissing or otherwise disciplining the Executive or authorizing legal action for breach of fiduciary duty.

 

 

 

OFFICER ACKNOWLEDGEMENT & AGREEMENT

PERTAINING TO THE FULGENT GENETICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY

This Acknowledgement & Agreement (the “Acknowledgement”) is delivered by the undersigned officer (“Executive”), as of the date set forth below, to Fulgent Genetics, Inc. (the “Company”). Executive is an employee of the Company (or one of its subsidiaries) who is serving as an “officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended.

Effective March 28, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of the Company adopted an Incentive Compensation Recoupment Policy, attached as Exhibit A hereto (as amended, restated, supplemented or otherwise modified from time to time by the Board, the “Recoupment Policy”). The Recoupment Policy provides for the recoupment of certain compensation from officers in the event the Compensation Committee of the Board determines that (a) such officer (i) engaged in serious misconduct, or (ii) failed to supervise a subordinate employee who engaged in serious misconduct which the Executive knew, or was reckless in not knowing, was occurring, and (b) such misconduct resulted in a material violation of law or a written Company policy that caused significant financial or reputational harm to the Company.

In consideration of the continued benefits to be received from the Company (and/or any subsidiary of the Company) and Executive’s right to participate in, and as a condition to the receipt of, Incentive Compensation (as defined in the Recoupment Policy), Executive hereby acknowledges and agrees to the following:

 

1.

Executive has read and understands the Recoupment Policy and has had an opportunity to ask questions to the Company regarding the Recoupment Policy.

 

2.

Executive agrees to be bound by and to abide by the terms of the Recoupment Policy and intends for the Recoupment Policy to be applied to the fullest extent of the law.

 

3.

The Recoupment Policy shall apply to any and all Incentive Compensation that is approved, awarded or granted to Executive on or after the Effective Date.

 

4.

In the event of any inconsistency between the provisions of the Recoupment Policy and this Acknowledgement or any applicable incentive-based compensation arrangements, employment agreement, equity agreement, indemnification agreement or similar agreement or arrangement setting forth the terms and conditions of any Incentive Compensation, the terms of the Recoupment Policy shall govern.

No modifications, waivers or amendments of the terms of this Acknowledgement shall be effective unless signed in writing by Executive and the Company. The provisions of this Acknowledgement shall inure to the benefit of the Company, and shall be binding upon, the successors, administrators, heirs, legal representatives and assigns of Executive.

By signing below, Executive agrees to the application of the Recoupment Policy and the other terms of this Acknowledgement.

 

______________________________________

Name:

 

 

 EX-101.SCH 3 flgt-20220328.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 flgt-20220328_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 flgt-20220328_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 28, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 28, 2022
Entity Registrant Name FULGENT GENETICS, INC.
Entity Central Index Key 0001674930
Entity File Number 001-37894
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-2621304
Entity Address, Address Line One 4978 Santa Anita Avenue
Entity Address, City or Town Temple City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91780
City Area Code 626
Local Phone Number 350-0537
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol FLGT
Security Exchange Name NASDAQ
XML 7 flgt-8k_20220328_htm.xml IDEA: XBRL DOCUMENT 0001674930 2022-03-28 2022-03-28 false 0001674930 8-K 2022-03-28 FULGENT GENETICS, INC. DE 001-37894 81-2621304 4978 Santa Anita Avenue Temple City CA 91780 626 350-0537 false false false false Common Stock, par value $0.0001 per share FLGT NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports flgt-8k_20220328.htm flgt-20220328.xsd flgt-20220328_lab.xml flgt-20220328_pre.xml flgt-ex101_7.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "flgt-8k_20220328.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "flgt-8k_20220328.htm" ] }, "labelLink": { "local": [ "flgt-20220328_lab.xml" ] }, "presentationLink": { "local": [ "flgt-20220328_pre.xml" ] }, "schema": { "local": [ "flgt-20220328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "flgt", "nsuri": "http://fulgentdiagnostics.com/20220328", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "flgt-8k_20220328.htm", "contextRef": "C_0001674930_20220328_20220328", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "flgt-8k_20220328.htm", "contextRef": "C_0001674930_20220328_20220328", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "verboseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "verboseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://fulgentdiagnostics.com/20220328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-22-012215-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-012215-xbrl.zip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�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